Last updated: 11/07/2018 16:29:02
This product has been transferred to Novartis. GSK Clinical Study Register is no longer maintained for this study. The most up to date information is available on clinicaltrials.gov.
Study Comparing GW572016 And Letrozole Versus Letrozole In Subjects With Advanced Or Metastatic Breast Cancer
Clinicaltrials.gov ID
EudraCT ID
EU CT Number
Not applicable
Trial status
No longer a GSK study
No longer a GSK study
Trial overview
Official title: A Randomized, Double-Blind, Placebo-Controlled, Multicenter, Phase III Study Comparing GW572016 and Letrozole versus Letrozole in Subjects with Estrogen/Progesterone Receptor-Positive Advanced or Metastatic Breast Cancer
Trial description: This study will compare the efficacy and tolerability of GW572016 administered in combination with letrozole, versus letrozole and placebo, as treatment for hormone receptor-positive advanced or metastatic breast cancer.
Primary purpose:
Treatment
Trial design:
Parallel Assignment
Masking:
Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Allocation:
Randomized
Primary outcomes:
Number of participants with progression free survival (PFS) in the human epidermal growth factor receptor 2 (HER2)-Positive Her3 as assessed by the Investigator
Timeframe: From the date of randomization until the date of the first documented progression or date of death from any cause, whichever came first, assessed for up to 46 months
Progression free survival (PFS) of participants in the HER2-Positive Population as assessed by the Investigator
Timeframe: From date of randomization until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 46 months
Secondary outcomes:
Duration of response for the participants with CR or PR in the HER2-Positive Population as assessed by the Investigator
Timeframe: Up to 46 months
Number of participants with evidence of brain metastases in the HER2-Positive Population
Timeframe: Up to 46 months
Number of participants with the indicated expression of tumor by epidermal growth factor receptor (ErbB1/HER1/EGFR) at baseline
Timeframe: Baseline
Number of participants with clinical benefit categorized by HER2 ImmunoHistoChemistry (IHC) intensity
Timeframe: Up to 46 months
Number of participants with the indicated serious adverse events (SAEs) related to study drug reported by more than one participant in either treatment arm
Timeframe: Up to 46 months
Clinical benefit (CB) in the ITT Population as assessed by the Investigator
Timeframe: Up to 46 months
PFS in participants in the ITT Population as assessed by the Investigator
Timeframe: From date of randomization until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 46 months
Adjusted mean change from baseline for the FACT-B total score using observed data
Timeframe: Week 12, 24, 36, and 48 visits; conclusion/withdrawal visit
Number of participants with clinical benefit categorized by HER2 fluorescence in situ hybridization (FISH) status
Timeframe: Up to 46 months
Overall survival in the HER2-Positive Population
Timeframe: From date of randomization until date of death due to any cause, assessed up to 46 months
Number of participants with overall tumor response (OR) by stratification factors with measurable disease, including bone scans, in the HER2-Positive Population as assessed by the Investigator
Timeframe: Up to 46 months
Number of participants with evidence of brain metastases from the ITT Population
Timeframe: Up to 46 months
Number of participants with the indicated time to response for CR or PR in the HER2-Positive Population as assessed by the Investigator
Timeframe: Up to 46 months
Overall survival in the ITT Population
Timeframe: From date of randomization until date of death due to any cause, assessed up to 46 months
Time to progression (TTP) for the HER2-Positive Population as assessed by the Investigator
Timeframe: Up to 46 months
TTP for participants from the ITT Population as assessed by the Investigator
Timeframe: Up to 46 months
Number of participants with response in participants with baseline serum HER2 extracellular domain (ECD) baseline values greater than 15 nanograms per milliliter (ng/mL) and 15 ng/mL or lower
Timeframe: Up to 46 months
Number of HER2-Negative participants at baseline with and without seroconversion to a status of HER2 Positive
Timeframe: Up to 46 months
Number of participants with the indicated best response from the participants with measurable and non-measurable disease, including bone scans, in the ITT Population as assessed by the Investigator.
Timeframe: Up to 46 months
Duration of response for the participants with CR or PR in the ITT Population as assessed by the Investigator
Timeframe: Up to 46 months
Number of participants with the indicated time to response for CR or PR in the ITT Population as assessed by the Investigator
Timeframe: Up to 46 months
Time to seroconversion for participants who were HER2 Negative at baseline but became HER2 Positive
Timeframe: Up to 46 months
Adjusted mean change from baseline for the trial outcome index (TOI) score using observed data
Timeframe: Week 12, 24, 36, and 48 visits; conclusion/withdrawal visit
Number of participants classified as QOL responders based on the FACT-B, FACT-G, and TOI total scores
Timeframe: Up to 46 months
Number of participants with the indicated adverse events (AEs) related to study treatment reported in 10% or more participants in either treatment arm
Timeframe: Up to 46 months
Number of participants completing the functional assessment of cancer therapy-breast (FACT-B) questionnaire at the scheduled visits
Timeframe: Day 1 (baseline) visit; Week 12, 24, 36, 48, 60, 72, 84, 96, 108, 120, 132, 144, 156, 168, 180, and 192 visits; conclusion/withdrawal visit
Clinical benefit (CB) in the HER2-Positive Population as assessed by the Investigator
Timeframe: Up to 46 months
Overall tumor response (OR) for participants with measurable and non-measurable disease, including bone scans, in the ITT Population as assessed by the Investigator
Timeframe: Up to 46 months
Number of participants with overall tumor response (OR) by stratification factors with measurable disease, including bone scans, in the ITT Population as assessed by the Investigator
Timeframe: Up to 46 months
Adjusted mean change from baseline for the Functional Assessment of Cancer Therapy-General (FACT-G) score using observed data
Timeframe: Week 12, 24, 36, and 48 visits; conclusion/withdrawal visit
Number of participants with the indicated best response from the participants with measurable and non-measurable disease, including bone scans, in the HER2-Positive Population as assessed by the Investigator.
Timeframe: Up to 46 months
Overall tumor response (OR) for participants with measurable and non-measurable disease, including bone scans, in the HER2-Positive Population as assessed by the Investigator
Timeframe: Up to 46 months
Number of participants with PFS in the Intent-To-Treat (ITT) Population as assessed by the Investigator
Timeframe: From date of randomization until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 46 months
Interventions:
Drug: Lapatinib (GW572016)
Drug: Letrozole
Enrollment:
1286
Observational study model:
Not applicable
Primary completion date:
2008-03-06
Time perspective:
Not applicable
Clinical publications:
Finn R, Press M, Dering J, O’Rourke L, Florance A, Ellis C, Martin A, Johnston S .Quantitative ER and PgR Assessment as Predictors of Benefit From Lapatinib in a Phase III Double-Blinded Randomized Trial of Postmenopausal Women With Hormone Receptor-Positive, HER-2 Negative Metastatic Breast Cancer Treated With Letrozole and Lapatinib or Letrozole and Placebo .Clin. Cancer Res 2014;20(3):736-43
Schwarzberg L, Franco S, Florance A, O’Rourke L, Maltzman J, Johnston S . Lapatinib plus Letrozole as First-Line Therapy for HER-2 Hormone Receptor–Positive Metastatic Breast Cancer. Oncologist. 2010;15:122-129.
Sherrill B, Amonkar M, Sherif B, Maltzman J, O'Rourke L, Johnston S. Quality of Life in Hormone Receptor Positive HER2+ Metastatic Breast Cancer Patients After Treatment With Letrozole Alone or in Combination With Lapatinib. The Oncologist. 2010;15:944-953.
Medical condition
Neoplasms, Breast
Product
lapatinib
Collaborators
Not applicable
Study date(s)
December 2003 to December 2016
Type
Interventional
Phase
2/3
Participation criteria
Sex
Female
Age
18+ years
Accepts healthy volunteers
none
- Signed informed consent;
- Subjects must have histologically confirmed invasive breast cancer with stage IV disease at primary diagnosis or at relapse after curative-intent surgery [Singletary, 2002];
- Pre-menopausal, pregnant, or lactating;
- Received prior chemotherapy, hormonal therapy, immunotherapy, biologic therapy, or anti-ErbB1/ErbB2 therapy for advanced or metastatic disease;
Inclusion and exclusion criteria
Inclusion criteria:
- Signed informed consent;
- Subjects must have histologically confirmed invasive breast cancer with stage IV disease at primary diagnosis or at relapse after curative-intent surgery [Singletary, 2002];
- Tumors that are ER+ and/or PgR+;
- Subjects will be considered ER+ or PgR+ if any assay [cytochemical, immunochemical, immunohistochemistry (IHC), or radioimmunoassay] of primary or secondary tumor tissue is positive;
- Post-menopausal female subjects =18 years of age;
- ECOG Performance Status of 0 or 1;
- Subjects must have archived tumor tissue available to compare tumor response with intra-tumoral expression of ErbB1 and ErbB2. Archived tumor tissue will also be used to confirm estrogen receptor (ER) and/or progesterone receptor (PgR) positivity. Results will not be used to determine subject eligibility for the study;
- Adjuvant therapy with an aromatase inhibitor is allowed; however, treatment must have ended more than 1 year prior (>12 months) to the first dose of randomized therapy;
- Adjuvant therapy with trastuzumab is allowed; however, treatment must have ended more than 1 year prior (>12 months) to the first dose of randomized therapy;
- Subjects who received neo-adjuvant/adjuvant therapy and now present with newly relapsed advanced or metastatic disease are eligible; however, prior neo-adjuvant/adjuvant therapy is not required for study entry; 11. Subjects must have ended hormone replacement therapy (HRT) (e.g., conjugated estrogens tablets, USP, [Premarin]), at least 1 month (30 days) prior to receiving the first dose of randomized therapy;
- Radiotherapy prior to initiation of randomized therapy is allowed to a limited area (e.g., palliative treatment for painful bone metastases), if it is not the sole site of disease. Subject must have completed treatment and recovered from all treatment related toxicities, in particular bone marrow suppression;
- Able to swallow and retain oral medication;
- Cardiac ejection fraction within the institutional range of normal as measured by echocardiogram (or MUGA scan if an echocardiogram cannot be performed or is inconclusive);
- Subjects must complete all screening assessments as outlined in the protocol;
- Adequate organ function
Exclusion criteria:
- Pre-menopausal, pregnant, or lactating;
- Received prior chemotherapy, hormonal therapy, immunotherapy, biologic therapy, or anti-ErbB1/ErbB2 therapy for advanced or metastatic disease;
- Bisphosphonate therapy for bone metastases is allowed; however, treatment must be initiated prior to the first dose of randomized therapy. Prophylactic use of bisphosphonates in subjects without bone disease, except for the treatment of osteoporosis, is not permitted;
- Malabsorption Syndrome, disease significantly affecting gastrointestinal function, or resection of the stomach or small bowel. Subjects with ulcerative colitis are also excluded;
- History of other malignancy. Subjects who have been disease-free for 5 years, or subjects with a history of completely resected non-melanoma skin cancer or successfully treated in situ carcinoma are eligible;
- Concurrent disease or condition that would make the subject inappropriate for study participation, or any serious medical disorder that would interfere with the subject's safety;
- Subjects who have not recovered from toxicities related to prior adjuvant therapy (e.g., surgery, radiotherapy, chemotherapy, hormonal therapy, immunotherapy, biologic therapy, and investigational agents);
- Subjects who have received anthracyclines in the neo-adjuvant and/or adjuvant setting, which exceeded the following doses: 360 mg/m2 of Doxorubicin, 720 mg/m2 of Epirubicin, and 72 mg/m2 of Mitoxantrone;
- Subjects with extensive symptomatic visceral disease including hepatic involvement and pulmonary lymphangitic spread of tumor, or the disease is considered by the investigator to be rapidly progressing or life threatening;
- Active or uncontrolled infection;
- Dementia, altered mental status, or any psychiatric condition that would prohibit the understanding or rendering of informed consent;
- Known history of uncontrolled or symptomatic angina, arrhythmias, or congestive heart failure;
- Known history of, or clinical evidence of, central nervous system (CNS) metastases or leptomeningeal carcinomatosis;
- Concurrent anti-cancer therapy (chemotherapy, radiation therapy, surgery, immunotherapy, hormonal therapy, targeted therapy, biologic therapy, or tumor embolization) other than letrozole;
- Concurrent treatment with an investigational agent or participation in another clinical trial;
- Used an investigational drug within 30 days or 5 half-lives, whichever is longer, preceding the first dose of randomized therapy (GW572016 or placebo);
- The subject has a known immediate or delayed hypersensitivity reaction or idiosyncrasy to drugs chemically related to randomized therapy (GW572016 or placebo) or to excipients of randomized therapy (GW572016 or placebo); 18. Subject has known hypersensitivity to Femara or excipients of Femara
Trial location(s)
No location data available.
Study documents
Clinical study report
Available language(s): English
Scientific result summary
Available language(s): English
If you wish to request for full study report, please contact - [email protected]
Results overview
Refer to study documents
Recruitment status
No longer a GSK study
Actual primary completion date
2008-03-06
Actual study completion date
Not applicable
Plain language summaries
Plain language summaries of clinical trial results for Phase 2-4 clinical trials that were initiated on or after January 2022 will be posted by GSK within one year following study completion.
Additional information about the trial
Additional information
Not applicable
Participate in clinical trial
Access to clinical trial data by researchers
Visit website